Asgard Therapeutics was shortlisted as a finalist of the 2021 Merck EU Advance Biotech Grants Program. This program aims to support emerging biotech companies pushing innovative drugs to the market by allowing grant recipients to receive free products and services.
Asgard Therapeutics was awarded with Sweden’s SWElife innovation grant to support the project “Turning head and neck cancer into immune cells: preclinical validation and clinical plan of TrojanDC” in collaboration with Dr. Lennart Greiff from the Department of Otorhinolaryngology, Head & Neck Surgery, Skåne University Hospital (Lund) and Professor Malin Lindstedt from the Department of Immunotechnology at Lund University. The purpose of this project is to perform preclinical validation and clinical trial design of TrojanDC for Head & Neck cancer treatment.
Swelife is a strategic innovation programe, funded by the Swedish Government via the Swedish innovation agency, Vinnova, and by the programe’s partners. Swelife supports collaboration within academia, industry and healthcare, with the goal to strengthen Life Science in Sweden and to improve public health.
Rapidus and PwC highlighted Fábio Rosa as one of 34 young promising Scanian personalities and driven entrepreneurs of this year.
In a new survey published by Øresund Institute and Medicon Valley Alliance, Asgard Therapeutics was highlighted as one of 426 life science companies in Skåne.
Mats Paulsson Foundations awarded Filipe Pereira, co-founder of Asgard Therapeutics, with a Mats Paulsson Grant 2020. Since 2019, the foundation has focused on grants for academic research projects that in the near future can lead to socially beneficial innovations.
The KiiLN- Keystone for Incubating Innovation in Life Sciences Network team and Icahn School of Medicine at Mount Sinai awarded Filipe Pereira, co-founder of Asgard Therapeutics, the KiiLN Postdoctoral Entrepreneurship Award. This award recognizes Filipe’s efforts in entrepreneurship addressing unmet needs in life sciences.
Asgard Therapeutics AB has been admitted to SmiLe Incubator as the next step to move forward on the pre-clinical studies of their lead program TrojanDC.
Advanced Therapies Medical Products (ATMPs) are considered the “drugs of the future”. These are based on gene, cell and tissue products. Sweden has the ambitious goal of becoming a leader in ATMPs and for this it is important to manage research efforts in an efficient way, facilitating the clinical translation of such innovative therapies. Within this thematic, Pharma Industry Publishing AB published a report on the development of ATMPs in Sweden, where Asgard Therapeutics was featured.
Together with Sparbanken Skåne, in collaboration with the Sparbanksstiftelsen Finn, Lund University awarded Filipe Pereira, Cristiana Pires and Fábio Rosa the Lund University and Sparbanken Skåne’s prize for future innovations. The award is intended to promote and encourage the utilization of knowledge at Lund University.
The BioInnovation Institute (BII) awarded Filipe Pereira, co-founder of Asgard Therapeutics, with DKK 3.5M to advance pre-clinical development of dendritic cell reprogramming and define its regulatory roadmap towards the clinic.